A phase I dose escalation trial to evaluate the safety and tolerability of CP-675,206 administered in combination with SU011248 to patients with treatment naive metastatic renal cell carcinoma.
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2012
At a glance
- Drugs Sunitinib; Tremelimumab
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors AstraZeneca
- 05 Jun 2012 Company added in association field as reported by ClinicalTrials.gov.
- 30 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jun 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.